Therma portfolio co. completes FIH stroke cohort

Executive Summary

• Inretio, a portfolio company of Therma Bright, successfully completed the first cohort of its first-in-human (FIH) study for the PREVA neuro-thrombectomy system.
• Following a positive review by the Data Safety Monitoring Board (DSMB), Inretio has received approval to continue patient enrollment and is targeting a U.S. FDA pivotal trial.
• The company aims to secure an Investigational Device Exemption (IDE) to launch a multicentre U.S. study later this year, with the trial expected to conclude within 24 months.

Key Details

• Clinical Milestone: Completion of the first cohort of the first-in-human study for the PREVA neuro-thrombectomy system.
• Regulatory Status: Received approval from the Data Safety Monitoring Board (DSMB) to continue patient enrollment; preparing for submission to the U.S. Food and Drug Administration (FDA).
• Future Trials: Targeting an Investigational Device Exemption (IDE) for a multicentre U.S. study planned for later this year, designed to conclude within 24 months.
• Product Development: The PREVA system is being refined based on direct physician feedback to ensure superior clinical utility.
• Operational Scaling: Inretio is upgrading manufacturing capabilities, including expanding facilities and integrating manufacturing enhancements, to meet the demands of the pivotal trial.
• Capital Raise: Inretio is currently advancing a capital raise to support the U.S. regulatory process, clinical operations, and manufacturing scaling.
• Market Context: Cited CDC data indicating ischemic stroke accounts for ~87% of all strokes, affecting nearly 8 million people globally per year, with incidence rates rising due to an aging population.

Notable Quotes

• Raviv Vine, CEO of Inretio: "We are executing with precision across all critical fronts... The positive DSMB feedback validates our safety profile and provides a strong foundation for our U.S. strategy. As we prepare for our FDA submission, we are simultaneously refining the PREVA system based on direct physician feedback to ensure superior clinical utility."
• Rob Fia, CEO of Therma Bright: "We are thrilled by Inretio's rapid progress and the definitive steps taken toward commercialization... We look forward to a transformative 2026."